ストックスクリーナーアプリを入手
8.63
1.89%
0.16
アフターアワーズ：
8.50
-0.13
-1.51%
前日終値:
$8.47
開ける：
$8.54
24時間の取引高:
2.42M
Relative Volume:
2.05
時価総額：
$731.79M
収益：
-
当期純損益:
$-43.16M
株価収益率:
-13.08
EPS:
-0.66
ネットキャッシュフロー:
$-29.31M
1週間 パフォーマンス:
+2.01%
1か月 パフォーマンス:
+1.83%
6か月 パフォーマンス:
+117.38%
1年 パフォーマンス:
-2.49%
1日の値動き範囲:
$8.26
$8.78
1週間の範囲:
$8.26
$9.48
52週間の値動き範囲:
$3.25
$10.45
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
名前
Anavex Life Sciences Corporation
セクター
電話
844-689-3939
住所
630 5TH AVENUE, NEW YORK
AVXL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
8.63 | 731.79M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-09-23 | 開始されました | BTIG Research | Buy |
| 2020-12-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-28 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-02-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 開始されました | Janney | Buy |
| 2018-05-16 | 再開されました | Maxim Group | Buy |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-02-07 | 開始されました | Noble Financial | Buy |
| 2016-03-29 | 開始されました | FBR Capital | Outperform |
すべてを表示
Anavex Life Sciences Corporation (AVXL) 最新ニュース
Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 8.5%Time to Buy? - MarketBeat
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 - The Manila Times
Anavex Life Sciences Sets Date for Q4 2024 Earnings Release and Strategic Update - StockTitan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Up – Should You Buy? - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap UpShould You Buy? - MarketBeat
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference - The Manila Times
Anavex to Unveil 4-Year Alzheimer's Drug Data at JPM Healthcare Conference - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 7.8% – Here’s What Happened - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 7.8%What's Next? - MarketBeat
Anavex Life Sciences (LTS:0HFR) EPS (Diluted) : $-0.51 (TTM As of Jun. 2024) - GuruFocus.com
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 - The Manila Times
Anavex Life Sciences to Present at Major Evercore ISI Healthcare Conference - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Trading 8.1% HigherShould You Buy? - MarketBeat
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC Wainwright - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Earns “Buy” Rating from D. Boral Capital - Defense World
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA - The Manila Times
Anavex Submits Breakthrough Oral Alzheimer's Drug to European Regulators | AVXL Stock News - StockTitan
Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal - The Manila Times
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 4.1%Time to Sell? - MarketBeat
Nwam LLC Purchases New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by GSA Capital Partners LLP - MarketBeat
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Reaches New 52-Week HighShould You Buy? - MarketBeat
Insider Bets Paying Off At AVXL As New 52-Week High Reached - Nasdaq
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 8.1%Here's Why - MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha
Anavex: Understanding Their Latest Alzheimer's Data News With Caution (NASDAQ:AVXL) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - The Manila Times
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright - MarketBeat
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - StockTitan
Anavex reports positive EEG results in schizophrenia trial - Investing.com
Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Declines By 10.3% - MarketBeat
Examining Anavex Life Sciences Corporation (AVXL) stock is warranted - US Post News
Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Market Insights: Anavex Life Sciences Corporation (AVXL)’s Notable Drop of -2.42, Closing at 5.24 - The Dwinnex
Understanding the Risks of Investing in Anavex Life Sciences Corporation (AVXL) - Knox Daily
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade) (NASDAQ:AVXL) - Seeking Alpha
The time has not yet come to remove your chips from the table: Anavex Life Sciences Corporation (AVXL) - SETE News
Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
A stock that deserves closer examination: Anavex Life Sciences Corporation (AVXL) - US Post News
Anavex Life Sciences Corporation (AVXL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Anavex Life Sciences Corporation [AVXL] Director makes an insider acquire of 2,835 shares worth 10,319. - Knox Daily
Australian Vanadium gets interest for $31 million finance support - Mining.com.au
Anavex Life Sciences Corporation (AVXL) 財務データ
収益
当期純利益
現金流量
EPS
Anavex Life Sciences Corporation (AVXL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
May 15 '24 |
Buy |
4.52 |
5,000 |
22,600 |
5,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 28 '24 |
Option Exercise |
1.32 |
73,380 |
96,862 |
1,323,590 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 28 '24 |
Sale |
5.11 |
73,380 |
374,972 |
1,250,210 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):